Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Cerus Corporation CERS

Healthcare — Medical Devices

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
3.09
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 — — — 9 — 2 5 1 1 —
Insider Ownership
4.93%

Capital & Financial Ratios

Market Cap
530.01
Revenue
248.01
Net Income
(6.83)
Free Cash Flow
(1.83)
Net Debt
8.65
Current Ratio
1.83
Debt/Equity
0.92
P/E ratio
0.00
P/S ratio
2.14
P/B ratio
7.52
Past 5Y EPS Growth
25.97%
This Y EPS Growth
43.75%
Next Y EPS Growth
72.22%
Next 5Y EPS Growth
54.33%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 65.85 80.45 82.88 56.26
Receivables 35.50 29.78 30.37 30.98
Inventory 39.87 38.15 56.10 65.81
Other — — — —
144.44 152.02 174.38 157.31
2023 2024 2025 Q'26
Payables 23.84 21.70 28.01 33.52
ST’ Debt 20.00 19.30 43.34 30.09
Other — — — —
67.52 63.61 100.80 85.79
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 59.89 63.30 — —
—
’25 48.85 60.13 60.24 64.58
233.80
’24 43.40 50.52 50.66 56.75
201.32
’23 38.48 47.73 47.25 53.34
186.80
’22 43.02 47.63 46.34 51.32
188.32
’21 29.57 37.76 42.10 50.09
159.52
’20 24.64 26.83 29.19 33.59
114.25
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (3.05) (2.66) — —
—
’25 (0.84) (2.45) 1.93 6.20
4.84
’24 1.96 0.40 4.07 4.93
11.36
’23 (8.50) (9.00) (10.49) (15.18)
(43.17)
’22 (21.46) (0.34) (2.06) (1.76)
(25.61)
’21 (17.45) (8.66) (6.58) (1.22)
(33.92)
’20 (19.80) (7.92) (5.19) (8.90)
(41.81)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (3.28) (3.53) — —
—
’25 (0.96) (2.92) 0.09 4.89
1.11
’24 0.86 0.36 3.35 3.95
8.52
’23 (10.02) (9.44) (13.12) (15.18)
(47.76)
’22 (21.57) (0.42) (2.63) 37.11
12.49
’21 (17.65) (8.69) (6.80) (1.69)
(34.83)
’20 (20.25) (8.37) (5.43) (9.37)
(43.43)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.01) (0.01) — —
—
’25 (0.04) (0.03) 0.00 (0.01)
(0.08)
’24 (0.05) (0.03) (0.02) (0.01)
(0.11)
’23 (0.09) (0.07) (0.04) (0.01)
(0.21)
’22 (0.07) (0.05) (0.05) (0.08)
(0.24)
’21 (0.10) (0.09) (0.07) (0.05)
(0.32)
’20 (0.10) (0.09) (0.08) (0.09)
(0.37)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.25 1.21 1.38 1.12 — — —
Low Price
‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 7.01 4.05 2.59 2.26 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 309 288 281 275 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.61 0.65 0.72 0.85 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 188.32 186.80 201.32 233.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 60.20% 62.54% 59.89% 59.86% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.34) (37.32) (20.76) (15.28) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (22.48%) (19.98%) (10.31%) (6.54%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.82) (37.65) (20.96) (15.64) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.98 2.60 1.86 1.43 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.07 1.04 1.09 1.23 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.24) (0.21) (0.11) (0.08) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.15) (0.24) 0.06 0.03 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.22 (0.03) (0.02) (0.02) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.07 (0.26) 0.05 0.01 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.39 0.30 0.31 0.34 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 176.55 180.27 184.56 190.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.51 2.08 1.41 1.68 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.63 7.29 5.00 6.04 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.33 2.16 1.43 1.68 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 50.28 (8.44) 33.79 355.26 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (25.61) (43.17) 11.36 4.84 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 38.10 (4.60) (2.84) (3.73) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.49 (47.76) 8.52 1.11 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 53.09 76.92 88.41 73.58 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 69.80 79.80 84.16 83.89 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.35) 13.94 3.71 1.01 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 68.56 53.44 56.90 64.97 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.78%) (18.03%) (10.49%) (7.39%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.82%) (27.87%) (14.67%) (8.22%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (55.49%) (61.45%) (37.92%) (25.65%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Cerus Corporation (CERS) has engineered impressive revenue growth, expanding from $39 million in 2016 to over $201 million in 2024 at a 26% CAGR, driven by its INTERCEPT Blood System’s pathogen inactivation technology and key FDA approvals like the 2022 platelet clearance. This has fueled U.S. market penetration amid rising blood safety demands, with projections showing steady 9-10% annual increases to $265 million by 2027. Operational efficiency shines through, with revenue per employee tripling to $716,000 and gross margins stable near 60%, underscoring scalable economics in a capital-intensive sector.

The path to profitability is materializing cautiously, with losses narrowing 67% to -$21 million in 2024 and free cash flow swinging to a robust +$46 million, bolstering a resilient balance sheet featuring $88 million in working capital and minimal net debt of $3.7 million. Valuation metrics are compellingly low—P/S at 1.4x, a steep discount to peers—trading at levels that suggest re-rating potential as earnings turn positive by 2027, though insider selling tempers unbridled optimism.

While risks like regulatory hurdles persist, Cerus’s fortress-like liquidity and FCF generation position it as a steady biotech contender in the $5B+ transfusion market, with analyst targets implying 80-120% upside. For those prioritizing balance sheet strength amid growth, this merits deeper scrutiny.

Read full commentary →

Cerus Corporation (CERS) Latest News

News by impact score

Fine-tune

30 Jul

3 transcript www.marketbeat.com, 6:04 PM
Cerus Corporation conducted its Q2 earnings call, covering financial results, operational metrics, and forward outlook for the blood transfusion company. Q2 earnings call highlights typically deliver quarterly financial updates that can shift near-term investor views but rarely trigger fundamental long-term changes.

3 , 4:01 PM
Cerus Corporation announced its second quarter 2026 financial results. Quarterly earnings releases deliver performance data that can shift near-term investor views without guaranteeing major strategic change.

16 Jun

4 , 8:53 AM
Cerus Corporation closed a new debt facility of up to $110 million. New debt facility of up to $110 million supplies major capital that strengthens financial position and supports growth plans.

8 Jun

3 Business Wire, 8:30 AM
Cerus Corporation closed a new debt facility of up to $110 million. New debt facility supplies Cerus with material liquidity to fund operations and growth.

1 May

4 app.moby.co, 8:30 AM
Cerus Corporation released Q1 2026 earnings call summary highlighting quarterly financial performance, operational updates, and forward guidance. Q1 earnings call summary details financial results and strategic outlook that significantly influence investor sentiment and stock trajectory.

4 GuruFocus.com, 3:17 AM
Cerus Corporation reported strong revenue growth in Q1 2026 earnings call, highlighting strategic initiatives amid positive financial performance. Strong revenue growth combined with strategic highlights signals major positive shifts in financials and competitive positioning.

30 Apr

4 transcript www.fool.com, 7:26 PM
Cerus Corporation (CERS) released its Q1 2026 earnings call transcript, covering financial results, operational updates, and forward-looking guidance. Q1 earnings transcripts disclose quarterly financials, management insights, and strategic outlook capable of significantly shifting investor sentiment and stock trajectory.

4 www.marketbeat.com, 6:16 PM
Cerus Corporation (CERS) shared Q1 earnings call highlights, covering financial results, operational updates, and forward guidance. Q1 earnings highlights detail financial performance, product progress, and strategic outlook with potential to shift stock trajectory and investor confidence.

3 Business Wire, 4:01 PM
Cerus Corporation announced first quarter 2026 financial results. Q1 2026 earnings announcement affects financial performance and investor sentiment but represents routine quarterly reporting.

27 Apr

4 Business Wire, 8:00 AM
Cerus Corporation announced a new four-year supply agreement with a French blood establishment for the INTERCEPT Blood System. Four-year supply agreement secures recurring revenue and strengthens European market presence.

16 Mar

4 Business Wire, 4:05 PM
Cerus Corporation appointed Vivek Jayaraman as President and Chief Executive Officer. CEO appointment signals major leadership transition with potential to reshape strategic direction and investor confidence.

7 Mar

4 www.marketbeat.com, 10:05 PM
Cerus Corporation detailed INTERCEPT growth plan, BCA deal upside, and 2026 RBC milestones at TD Cowen Conference. Detailed growth strategies, deal benefits, and product milestones signal major advancements in Cerus's blood safety portfolio and revenue trajectory.

3 Mar

4 app.moby.co, 8:30 AM
Cerus Corporation released Q4 2025 earnings call summary, covering financial results, operational updates, product developments, and forward guidance. Q4 earnings summaries disclose critical financial metrics and strategic plans significantly influencing stock performance and investor outlook.

4 GuruFocus.com, 12:02 AM
Cerus Corp (CERS) reported record revenue growth in Q4 2025 earnings call, alongside strategic advancements boosting future outlook. Record revenue growth and strategic highlights indicate major positive shifts in financial trajectory and investor sentiment.

2 Mar

4 transcript www.fool.com, 5:49 PM
Cerus Corporation (CERS) Q4 2025 earnings call transcript released, detailing quarterly financial results, operational updates, and forward guidance. Q4 earnings call transcripts reveal financial performance, strategic updates, and guidance that significantly influence stock trajectory and investor sentiment.

4 Associated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceSimply Wall St.Associated Press FinanceAssociated Press Finance, 4:15 PM
Cerus Corporation released Q4 earnings snapshot detailing financial performance for the quarter. Q4 earnings directly impact Cerus's financial trajectory and investor sentiment.

4 Business Wire, 4:01 PM
Cerus Corporation announced full-year and fourth quarter 2025 financial results. Full-year and Q4 financial results announcements directly impact stock price, investor sentiment, and assessments of operational health.

3 www.marketbeat.com, 6:27 PM
Cerus Corporation released highlights from its Q4 earnings call, covering financial results, operational updates, and future outlook. Q4 earnings call highlights moderately influence financial performance and investor sentiment without fundamental trajectory changes.

22 Jan

4 Business Wire, 7:30 AM
The DRK Blood Donation Service Baden-Württemberg – Hessen has initiated a study to evaluate the use of pathogen-inactivated platelet concentrates treated with Cerus Corporation's INTERCEPT™ Blood System in routine clinical practice. This study aims to assess the safety and efficacy of the INTERCEPT technology in blood transfusions, potentially enhancing patient outcomes and safety standards in transfusion medicine. The initiation of this study could significantly impact Cerus Corporation's market position and investor sentiment regarding its INTERCEPT technology.

13 Jan

4 Simply Wall St., 7:05 AM
Cerus Corporation (CERS) is highlighted as a promising penny stock with a market cap exceeding $100 million. The company focuses on developing innovative blood safety technologies, particularly its INTERCEPT Blood System, which aims to enhance the safety of blood transfusions. Recent advancements and partnerships have positioned Cerus favorably within the healthcare sector, attracting investor interest. The stock's potential for growth is underscored by its strategic initiatives and the increasing demand for blood safety solutions. Cerus Corporation's advancements in blood safety technology and strategic partnerships are likely to significantly impact its market position and investor sentiment.

11 Jan

4 Business WireMT NewswiresBarchartMarketBeatMT NewswiresSimply Wall St.Simply Wall St.MT Newswires, 4:00 PM
Cerus Corporation reported preliminary product revenue for the fourth quarter and full year of 2025, indicating growth and positive trends in its financial performance. The company provided an optimistic outlook for future revenue, driven by increased demand for its blood safety products and strategic initiatives aimed at expanding market reach. Management highlighted key factors contributing to this growth, including successful product launches and enhanced operational efficiencies. The announcement of preliminary revenue figures and a positive outlook suggests significant growth potential and strategic advancements that could impact investor sentiment and market performance.

27 Dec

4 Insider Monkey, 7:43 AM
TD Cowen has identified Cerus Corporation (CERS) as having compelling long-term value, highlighting the company's potential for growth and innovation in the medical sector. Analysts suggest that Cerus is well-positioned to capitalize on market opportunities, which could enhance its financial performance and investor appeal. Cerus Corporation is expected to experience significant impact due to its strategic positioning and potential market opportunities.

10 Dec

4 Business WireMT NewswiresPharmaceutical Technology, 4:15 PM
Cerus Corporation has entered into a group purchasing agreement with Blood Centers of America, which aims to enhance the availability of its INTERCEPT Blood System. This agreement is expected to streamline procurement processes for member blood centers, potentially increasing the adoption of Cerus' pathogen reduction technology in blood transfusions. The collaboration is anticipated to improve patient safety and expand market reach for Cerus. The agreement is a significant strategic move that could enhance market penetration and investor sentiment.

9 Dec

4 Simply Wall St., 1:05 PM
Cerus Corporation (CERS) is highlighted as a promising penny stock for December 2025, driven by its innovative blood safety technologies and potential market growth. The company is focusing on expanding its product offerings and enhancing its competitive position in the healthcare sector. Investors are encouraged to monitor Cerus for potential gains as it navigates upcoming developments and market dynamics. Cerus Corporation is poised for significant impact due to its strategic initiatives and potential market expansion.

10 Nov

3 Simply Wall St., 7:04 AM
Cerus Corporation (CERS) is highlighted as a promising penny stock with a market cap under $400 million. The company focuses on blood safety and has developed the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections. Recent advancements and partnerships may enhance its market position. Investors are encouraged to consider the potential growth opportunities in the context of the broader market landscape. Cerus Corporation's advancements in blood safety technology may moderately influence its financial performance and competitive positioning.

7 Nov

4 GuruFocus.com, 12:01 AM
Cerus Corporation reported record revenue in Q3 2025, highlighting significant strategic shifts aimed at enhancing its market position. The earnings call emphasized the company's focus on innovation and expansion in its product offerings, which are expected to drive future growth. Management outlined plans to leverage new technologies and partnerships to strengthen its competitive edge in the industry. Significant strategic shifts and record revenue indicate a strong potential for future growth and improved market performance.

6 Nov

4 , 4:01 PM
Cerus Corporation reported record results for the third quarter of 2025, achieving significant growth in product revenue. The company has raised its full-year 2025 product revenue guidance, reflecting strong demand and operational performance. The raised revenue guidance indicates a significant positive shift in financial performance and market sentiment.

3 Associated Press Finance, 5:07 PM
Cerus Corporation reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its blood safety products, with ongoing efforts to expand market reach and enhance product offerings. Financial results showed a mix of growth and challenges, reflecting the competitive landscape and regulatory environment. Investors are keenly observing Cerus's strategic initiatives and their potential impact on future performance. The earnings report indicates moderate growth potential and operational challenges that could influence financial performance.

21 Oct

4 Business Wire, 8:30 AM
Cerus Corporation announced the presentation of abstracts and an industry workshop focused on its Intercept Blood System (IFC) at the upcoming 2025 AABB Annual Meeting. This event aims to highlight advancements and applications of the IFC technology in blood safety and transfusion practices, showcasing Cerus' commitment to innovation in the field. The workshop and abstracts at a major industry meeting could significantly enhance Cerus' visibility and influence in the blood safety market.

3 Simply Wall St., 7:39 AM
Cerus Corporation is highlighted as an undervalued small-cap stock with notable insider activity, suggesting potential growth and investment opportunities. The article emphasizes the importance of insider buying as a positive indicator for future performance, particularly in the context of the company's ongoing developments and market positioning. Insider buying indicates confidence in the company's future, which may moderately influence market sentiment and performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us